Atacand and Red cell distribution width increased - a phase IV clinical study of FDA data

Summary:

Red cell distribution width increased is reported as a side effect among people who take Atacand (candesartan cilexetil), especially for people who are female, 50-59 old, also take Fosamax, and have Breast cancer.

The phase IV clinical study analyzes which people have Red cell distribution width increased when taking Atacand. It is created by eHealthMe based on reports of 21,732 people who have side effects when taking Atacand from the FDA, and is updated regularly.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

What is Red cell distribution width increased?

Red cell distribution width increased is found to be associated with 604 drugs and 656 conditions by eHealthMe. Check the latest studies of Red cell distribution width increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 17, 2026

21,732 people reported to have side effects when taking Atacand.
Among them, 13 people (0.06%) have Red cell distribution width increased.

Could Atacand cause Red cell distribution width increased?

Among these 13 people:

What is the gender of people who have Red cell distribution width increased when taking Atacand? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Red cell distribution width increased when taking Atacand? *

What are other drugs people take besides Atacand? *

What are other side effects people have besides Red cell distribution width increased? *

Nausea And Vomiting: 9 people, 69.23%
Constipation: 9 people, 69.23%
Diarrhea: 9 people, 69.23%
Joint Pain: 9 people, 69.23%
Blood Glucose Increased: 9 people, 69.23%
Lymphoedema (localized fluid retention and tissue swelling): 6 people, 46.15%
Large Intestinal Ulcer: 6 people, 46.15%
Weight Increased: 6 people, 46.15%
Liver Function Test Abnormal: 6 people, 46.15%
Lung Neoplasm (tumour of lung): 6 people, 46.15%

What are the existing conditions these people have? *

Pain: 6 people, 46.15%
Metastases To Bone (cancer spreads to bone): 6 people, 46.15%
Breast Cancer: 6 people, 46.15%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 3 people, 23.08%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 7.69%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Atacand and have Red cell distribution width increased?

- Check whether Red cell distribution width increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atacand:

Atacand (22,473 reports)

Browse all side effects of Atacand:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red cell distribution width increased:

Red cell distribution width increased (604 drugs)

Browse all the conditions that are associated with Red cell distribution width increased:

Red cell distribution width increased (656 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on candesartan cilexetil (the active ingredients of Atacand) and Atacand (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.